Accutar Biotechnology Announces First Patient Dosed with AC0

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

, Jiaqi Ren , Accutar Biotechnology Inc , Chimeric Degrader With , Differentiated Mechanism , Removing Both Kinase And Scaffolding Functions , Coverage Designed , Overcome Resistance , Covalent And Non , Tyrosine Kinase , Lijie Fan , Chief Executive Officer , Accutar Biotechnology , Protein Interaction Targeting Chimera , Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Largeb Cell Lymphoma , Mantle Cell Lymphoma , Follicular Lymphoma , Marginal Zone Lymphoma ,